MarketCap
Facebook
X
TelegramQuarterly report 2023-Q1
added 05-22-2023
Nabriva Therapeutics plc Operating Cash Flow 2011-2026 | NBRV
Annual Operating Cash Flow Nabriva Therapeutics plc
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -36.7 M | -59.6 M | -71.3 M | -71.9 M | -72.7 M | -69.3 M | -48.3 M | -21.9 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -21.9 M | -72.7 M | -56.5 M |
Quarterly Operating Cash Flow Nabriva Therapeutics plc
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.62 M | - | -35.1 M | - | -15.9 M | - | -53.4 M | - | -21.6 M | - | -58 M | -45.4 M | -28.1 M | - | -56.4 M | -41.7 M | -20.6 M | - | -50.5 M | -33.4 M | -16.3 M | - | -45.3 M | -30.2 M | -14.7 M | - | -37.7 M | -25.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -5.62 M | -58 M | -33.4 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
-8.24 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
-18 M | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
99.9 M | - | 2.54 % | $ 160 B | France |
 |
Athira Pharma
ATHA
|
-45.7 M | - | - | $ 269 M | USA |
 |
Enlivex Therapeutics Ltd.
ENLV
|
-10.4 M | $ 0.77 | -4.12 % | $ 35.2 M |  Israel |
 |
Exelixis
EXEL
|
884 M | $ 48.16 | 4.22 % | $ 13.1 B | USA |
 |
BioNTech SE
BNTX
|
456 M | $ 94.13 | 1.19 % | $ 22.8 B | Germany |
 |
Fortress Biotech
FBIO
|
-65.8 M | $ 2.39 | -0.42 % | $ 66.7 M | USA |
|
Forte Biosciences
FBRX
|
-50.9 M | $ 24.02 | -8.22 % | $ 311 M | USA |
 |
Compugen Ltd.
CGEN
|
31.6 M | $ 2.9 | 1.4 % | $ 271 M | Israel |
 |
Checkmate Pharmaceuticals
CMPI
|
-53.7 M | - | - | $ 231 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
158 M | $ 22.4 | -0.71 % | $ 3.71 B | USA |
 |
Genmab A/S
GMAB
|
7.77 B | $ 26.43 | -2.33 % | $ 1.71 B |  Danmark |
 |
Advaxis
ADXS
|
-29.5 M | - | -9.65 % | $ 45.9 M | USA |
 |
Esperion Therapeutics
ESPR
|
-13.1 M | $ 3.14 | - | $ 653 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-8.95 M | $ 3.51 | -0.85 % | $ 5.78 M | Israel |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M | Canada |
 |
Gilead Sciences
GILD
|
10 B | $ 131.33 | -2.04 % | $ 163 B | USA |
 |
Genprex
GNPX
|
-15.3 M | $ 0.87 | 0.58 % | $ 811 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
22.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
-22 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-59.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-108 M | - | -0.23 % | $ 916 M | USA |
 |
Allakos
ALLK
|
-116 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
-38.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-5.62 M | $ 21.17 | 2.47 % | $ 2.69 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-45.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-8.56 M | - | -11.43 % | $ 502 K | USA |
|
Applied Molecular Transport
AMTI
|
-93.9 M | - | - | $ 10.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-43.8 M | - | - | $ 2.17 B | USA |
 |
Grifols, S.A.
GRFS
|
902 M | $ 8.1 | 0.5 % | $ 5.51 B |  Spain |
 |
Aileron Therapeutics
ALRN
|
-19.4 M | - | 10.36 % | $ 9.8 M | USA |
 |
Applied Therapeutics
APLT
|
-55.2 M | - | - | $ 8.42 M | USA |
 |
Aravive
ARAV
|
-65.1 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
-29.1 M | - | 17.91 % | $ 11.1 M | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-345 M | $ 54.83 | 4.6 % | $ 4.93 B |  Schweiz |
 |
Avenue Therapeutics
ATXI
|
-1.83 M | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-284 M | $ 1.57 | -2.48 % | $ 418 M | Britain |